Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)

Hepatology Research

Volumn 40, Issue 4, 2010, Pages 347-368

  Namiki, Izumi ^a   Nishiguchi, Shuhei ^b   Hino, Keisuke ^c   Suzuki, Fumitaka ^d   Kumada, Hiromitsu ^d   Itoh, Yoshihito ^e   Asahina, Yusuhiro ^a   Tamori, Akihiro ^f   Hiramatsu, Naoki ^g   Hayashi, Norio ^g   Kudo, Masatoshi ^h  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d TORANOMON HOSPITAL   (Japan)

^e KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^f OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g OSAKA UNIVERSITY   (Japan)

^h KINKI UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; Fibrosis of the liver; HCV mutation; Hepatocellular carcinoma; Peginterferon; Ribavirin

Indexed keywords

INTERFERON; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR;

AGE DISTRIBUTION; ANTIVIRAL THERAPY; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSENSUS DEVELOPMENT; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DISEASE COURSE; DOSE RESPONSE; DRUG MEGADOSE; DRUG WITHDRAWAL; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HEPATITIS C VIRUS; HOST RESISTANCE; HUMAN; JAPAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LOW DRUG DOSE; MEDICAL RESEARCH; MEDICAL SOCIETY; METABOLIC DISORDER; MONOTHERAPY; OXIDATIVE STRESS; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; THYROID DISEASE; UNITED STATES; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS MUTATION;

EID: 77954382326     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00642.x     Document Type: Article

References (172)

1. Ghany MG, Strader DB, Thomas DL. AASLD practice guidelines. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-74.
2. Shiffman RN, Shekelle P, Overhage J. Standard reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standadization. Ann Intern Med 2003, 139:493-98.
3. Pileri P, Uematsu Y, Campagnoli S. Binding of hepatitis C virus to CD81. Science 1998, 282:938-41.
4. Scarselli E, Ansuini H, Cerino R. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002, 21:5017-25.
5. Evans MJ, von Hahn T, Tscherne DM. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446:801-5.
6. Dubuisson J, Helle F, Cocquerel L. Early steps of the hepatitis C virus life cycle. Cell Microbiol 2008, 10:821-7.
7. Ploss A, Evans MJ, Gaysinskaya VA. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009, 457:882-6.
8. Flint M, von Hahn T, Zhang J. Diverse CD81 proteins support hepatitis C virus infection. J Virol 2006, 80:11331-42.
9. Sumpter R, Loo YM, Foy E. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005, 79:2689-99.
10. Yoneyama M, Kikuchi M, Natsukawa T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004, 5:730-7.
11. Li K, Chen Z, Kato N, Gale M, Lemon SM. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J Biol Chem 2005, 280:16739-47.
12. Kawai T, Takahashi K, Sato S. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 2005, 6:981-8.
13. Sen GC. Viruses and interferons. Annu Rev Microbiol 2001, 55:255-81.
14. Loo YM, Owen DM, Li K. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci USA 2006, 103:6001-6.
15. Gale M, Foy EM. Evasion of intracellular host defense by hepatitis C virus. Nature 2005, 436:939-45.
16. Bode JG, Ludwig S, Ehrhardt C. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 2003, 17:488-90.
17. Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002, 2:410-6.
18. Polyak SJ, Khabar KS, Paschal DM. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 2001, 75:6095-106.
19. Taylor DR, Shi ST, Romano PR. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999, 285:107-10.
20. Noguchi T, Satoh S, Noshi T. Effects of mutation in hepatitis C virus nonstructural protein 5A on interferon resistance mediated by inhibition of PKR kinase activity in mammalian cells. Microbiol Immunol 2001, 45:829-40.
21. Moriya K, Nakagawa K, Santa T. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001, 61:4365-70.
22. Okuda M, Li K, Beard MR. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002, 122:366-75.
23. Korenaga M, Wang T, Li Y. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 2005, 280:37481-8.
24. Shintani Y, Fujie H, Miyoshi H. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004, 126:840-8.
25. Kawaguchi T, Yoshida T, Harada M. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004, 165:1499-508.
26. Perlemuter G, Sabile A, Letteron P. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002, 16:185-94.
27. Moriishi K, Mochizuki R, Moriya K. Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci USA 2007, 104:1661-6.
28. Nishina S, Hino K, Korenaga M. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008, 134:226-38.
29. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 2008, 48:1420-9.
30. Veldt BJ, Chen W, Heathcote EJ. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008, 47:1856-62.
31. Ohata K, Hamasaki K, Toriyama K. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003, 97:3036-43.
32. Kato J, Kobune M, Nakamura T. Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 2001, 61:8697-702.
33. Furutani T, Hino K, Okuda M. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006, 130:2087-98.
34. Romero-Gomez M, Del Mar Viloria M, Andrade RJ. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005, 128:636-41.
35. Harrison SA, Brunt EM, Qazi RA. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005, 3:604-9.
36. Martinot-Peignoux M, Boyer N, Cazals-Hatem D. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001, 34:1000-5.
37. Castera L, Vergniol J, Foucher J. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-50.
38. Strader DB, Wright T, Thomas DI, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 38:1147-71.
39. Tsubota A, Chayama K, Ikeda K. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994, 19:1088-94.
40. Lau JY, Davis GL, Kniffen J. Significance of serum hepatitis C virus RNA in chronic hepatitis C. Lancet 1993, 341:1501-4.
41. Yamada G, Takatani M, Kishi F. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995, 22:1351-4.
42. Enomoto N, Sakuma I, Asahina Y. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. J Clin Invest 1995, 96:224-30.
43. Enomoto N, Sakuma I, Asahina Y. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996, 334:77-81.
44. Pascu M, Martus P, Hohne M. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 2004, 53:1345-54.
45. Shirakawa H, Matsumoto A, Joshita S. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008, 48:1753-60.
46. El-Shamy A, Nagano-Fujii M, Sasase N. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 2008, 48:38-47.
47. Akuta N, Suzuki F, Sezaki H. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005, 48:372-80.
48. Akuta N, Suzuki F, Kawamura Y. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007, 46:403-10.
49. Donlin MJ, Cannon NA, Yao E. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol 2007, 81:8211-24.
50. Akuta N, Suzuki F, Kawamura Y. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 2007, 46:1357-64.
51. Fishman SL, Factor SH, Balestrieri C. Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma. Clin Cancer Res 2009, 15:3205-13.
52. Ogata S, Florese RH, Nagano-Fujii M. Identification of hepatitis C virus (HCV) subtype 1b strains that are highly, or only weakly, associated with hepatocellular carcinoma on the basis of the secondary structure of an amino-terminal portion of the HCV NS3 protein. J Clin Microbiol 2003, 41:2835-41.
53. Nishise Y, Saito T, Sugahara K. Risk of hepatocellular carcinoma and secondary structure of hepatitis C virus (HCV) NS3 protein amino-terminus, in patients infected with HCV subtype 1b. J Infec Dis 2007, 196:1006-9.
54. Mattsson L, Sonnerborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-years follow-up study of hepatitis C virus markers. Liver 1993, 13:274-8.
55. Barrera JM, Bruguera M, Ercilla MG. Persistent hepatitis C viremia after self-limitng posttransfusion hepatitis C. Hepatology 1995, 21:639-44.
56. Amoroso P, Rapicetta M, Tosti ME. Correlation between virus genotype and chronicity rate in acute hepatitis C. J Hepatol 1998, 28:939-44.
57. Tanaka E, Kiyosawa K. Natural history of acute hepatitis C. J Gastroenterol Hepatol 2000, 15:E97-104.
58. Seeff LB, Buskell-Bales Z, Wright EC. Long-term mortality after transfusion-associated non-A, Non B hepatitis. N Engl J Med 1992, 327:1906-11.
59. Seeff LB, Miller RN, Rabkin CS. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000, 132:105-11.
60. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Eng J Med 1999, 340:1228-33. the Irish Hepatology Research Group
61. Kiyosawa K, Sodeyama T, Tanaka E. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990, 12:671-5.
62. Tong MJ, El-Farra NS, Reikes AR. Clinical outcomes after transfusion-associated hepatitis C. N Eng J Med 1995, 332:1463-6.
63. Ikeda K, Saitoh S, Koida I. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatojogy 1993, 18:47-53.
64. Yoshida H, Shiratori Y, Moriyama M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999, 131:174-81.
65. Okanoue T, Itoh Y, Minami M. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol 1999, 30:653-9.
66. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METEVIR, CLINIVIR and DOSVIRC groups. Lancet 1997, 349:825-32.
67. Shiratori Y, Imazeki F, Moriyama M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000, 132:517-24.
68. Persico M, Persico E, Suozzo R. Natural history of hepatitis C virus carriers with persistently normal aminotransferase. Gastroenterology 2000, 118:760-4.
69. Okanoue T, Makiyama A, Nakayama M. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol 2005, 43:599-605.
70. Tarao K, Rino Y, Ohkawa S. Association between high serum ALT and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients wit5h hepatitis C virus-associated cirrhosis. Cancer 1999, 86:589-94.
71. Kumada T, Toyoda H, Kiriyama S. Relation between incidence of hepatic cardcinhogenesis and integration value of alanine aminmotransferase in patients with hepatitis C virus infection. Gut 2007, 56:738-9.
72. Kumada T, Toyoda H, Kiriyama S. Long-term follow-up of patients with hepatitis C with a normal alanime aminotransferase. J Med Virol 2009, 81:446-51.
73. Suruki R, Hayashi K, Kusumoto K. Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan. Int J Cancer 2006, 119:192-5.
74. Makiyama A, Itoh Y, Kasahara A. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004, 101:1616-22.
75. Bruno S, Stroffolini T, Colombo M. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007, 45:579-87.
76. George S, Bacon BR, Brunt EM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009, 49:729-38.
77. Iino S, Okita K, Omata M. Clinical efficacy of PEG-Interferon alfa-2b and ribavirin combination therapy for 48 weeks in chronic hepatitis C patients with genotype 1 and high viral load -retrospective comparison with Interferon alfa-2b and ribavirin combination therapy for 24 weeks. Kantansui 2004, 49:1099-121.
78. Yamada G, Iino S, Okuno T. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig 2008, 28:9-16.
79. Akuta N, Suzuki F, Hirakawa M. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol 2009, 81:452-8.
80. Mangia A, Santoro R, Minerva N. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005, 352:2609-17.
81. Sezaki H, Suzuki F, Kawamura Y. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 2009, 54:1317-24.
82. Kogure T, Ueno Y, Fukushima K. Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. World J Gastroenterol 2008, 14:7225-4230.
83. Akuta N, Suzuki F, Kawamura Y. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2007, 79:1686-95.
84. Mizuta T, Kawaguchi Y, Eguchi Y. Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. Dig Dis Sci 2010, 55:183-9.
85. Tsukada H, Ochi H, Maekawa T. A Polymorphism in MAPKAPK3 Affects Response to Interferon Therapy for Chronic Hepatitis C. Gastroenterology 2009, 136:1796-805.
86. Asahina Y, Izumi N, Hirayama I. Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. Gastroenterology 2008, 134:1396-405.
87. Asahina Y, Izumi N, Umeda N. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. J Viral Hepat 2007, 14:396-403.
88. Sezaki H, Suzuki F, Kawamura Y. Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load. Hepatol Res 2007, 37:787-92.
89. Berg T, von Wagner M, Nasser S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-Alfa-2a plus ribavirin. Gastroenterology 2006, 130:1086-109.
90. Sanchez-Tapias JM, Diago M, Escartin P. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006, 131:451-60.
91. Ferenci P, Laferl H, Scherzer TM. Customizing treatment with peginterferon alfa-2a (40kD) (PEGASYS®) plus ribavirin (COPEGUS®) in patient with HCV genotype 1 or 4 infection: interim results of a prospective randomized trial. Hepatology 2006, 44:336a.
92. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007, 46:1688-94.
93. Buti M, Lurie Y, Zakharova NG. Extended treatment duration in chronic hepatitis C genotype 1-infected slow responders: final results of the SUCCESS study (abstract #141). J Hepatol 2009, 50(1):S58. Suppl
94. Ide T, Hino T, Ogata K. A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C. Am J Gastroenterol 2009, 104:70-5.
95. von Wagner M, Huber M, Berg T. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005, 129:522-7.
96. Shiffman ML, Suter F, Bacon BR. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007, 357:124-34.
97. Dalgard O, Bjøro K, Ring-Larsen H. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008, 47:35-42.
98. Lagging M, Langeland N, Pedersen C. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008, 47:1837-45.
99. Yu ML, Dai CY, Huang JF. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007, 56:553-9.
100. Mangia A, Minerva N, Bacca D. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 2009, 49:358-63.
101. Manns MP, McHutchison JG, Gordon SC. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-65.
102. Fried MW, Shiffman ML, Reddy KR. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-82.
103. Hadziyannis SJ, Sette H, Morgan TR. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-55.
104. Helbling B, Jochum W, Stamenic I. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat 2006, 13:762-9.
105. Bergmann JF, Vrolijk JM, van der Schaar P. Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. Liver Int 2007, 27:1217-25.
106. Diago M, Crespo J, Olveira A. Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. Aliment Pharmacol Ther 2007, 26:1131-8.
107. Carr C, Hollinger FB, Yoffe B. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C. Liver Int 2007, 27:1111-8.
108. Mathew A, Peiffer LP, Rhoades K. Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment. Dig Dis Sci 2006, 51:1956-61.
109. Jacobson IM, Gonzalez SA, Ahmed F. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005, 100:2453-62.
110. Herrine SK, Brown RS, Bernstein DE. Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. Dig Dis Sci 2005, 50:719-26.
111. Shiffman ML, Di Bisceglie AM, Lindsay KL. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004, 126:1015-23.
112. Jensen DM, Marcellin P, Freilich B. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009, 150:528-40.
113. Poynard T, Colombo M, Bruix J. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009, 136:1618-28.
114. Di Bisceglie AM, Shiffman ML, Everson GT. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008, 359:2429-41.
115. McHutchison JG, Gordon SC, Schiff ER. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1485-92.
116. Poynard T, Marcellin P, Lee SS. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352:1426-32.
117. Davis GL, Esteban-Mur R, Rustgi V. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1493-9.
118. Reichard O, Norkrans G, Frydén A. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998, 351:83-7.
119. Zeuzem S, Feinman SV, Rasenack J. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000, 343:1666-72.
120. Lindsay KL, Trepo C, Heintges T. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001, 34:395-403.
121. Pockros PJ, Carithers R, Desmond P. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol 2004, 99:1298-305.
122. Akuta N, Suzuki F, Tsubota A. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. J Hepatol 2002, 37:831-6.
123. Iwasaki Y, Shiratori Y, Hige S, NIshiguchi S. A randomized trial of 24 versus 48 weeks of peginterferon a-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan. Hepatol Int 2009, 3:468-79.
124. Masuko K, Okuda K, Meguro T. Hepatitis C virus antibodies, viral RNA and genotypes in sera from patients on maintenance haemodialysis. J Viral Hepat 1994, 1:65-71.
125. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004, 20:1271-7.
126. Rostaing L, Chatelut E, Payen JL. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998, 9:2344-8.
127. Russo MW, Goldsweig CD, Jacobson IM, Brown RS. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003, 98:1610-5.
128. Fabrizi F, Dixit V, Messa P, Martin P. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2008, 15:79-88.
129. Kamar N, Ribes D, Izopet J, Rostaing L. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. Transplantation 2006, 82:853-6.
130. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int Suppl 2008, 109:S1-99.
131. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006, 13:34-41.
132. Ikeda K, Arase Y, Kawamura Y. Necessities of Interferon Therapy in Elderly Patients with Chronic Hepatitis C. Am J Med 2009, 122:479-86.
133. Ikeda K, Arase Y, Saitoh S. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000, 32:228-32.
134. Kubo S, Nishiguchi S, Hirohashi K. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001, 134:963-7.
135. Shiratori Y, Shiina S, Teratani T. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003, 138:299-306.
136. Mazzaferro V, Romito R, Schiavo M. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006, 44:1543-54.
137. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002, 89:418-22.
138. Shiratori Y, Ito Y, Yokosuka O. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005, 142:105-14.
139. Nishiguchi S, Kuroki T, Nakatani S. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995, 346:1051-5.
140. Ikeda K, Saitoh S, Arase Y. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999, 29:1124-30.
141. Imai Y, Kawata S, Tamura S. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998, 129:94-9.
142. Arase Y, Ikeda K, Suzuki F. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. J Med Virol 2007, 79:1095-102.
143. Nomura H, Kashiwagi Y, Hirano R. Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: A pilot study. Hepatol Res 2007, 37:490-7.
144. Shiffman ML, Hofmann CM, Contos MJ. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999, 117:1164-72.
145. Saito Y, Saito H, Tada S. Effect of long-term interferon therapy for refractory chronic hepatitis c: preventive effect on hepatocarcinogenesis. Hepatogastroenterology 2005, 52:1491-6.
146. Arase Y, Ikeda K, Suzuki F. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. J Med Virol 2007, 79:1485-90.
147. Akuta N, Suzuki F, Kawamura Y. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy. J Med Virol 2008, 80:1363-9.
148. Imai Y, Kasahara A, Tanaka H. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. J Gastroenterol 2004, 39:1069-77.
149. Iwasaki Y, Ikeda H, Araki Y. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006, 43:54-63.
150. Hiramatsu N, Oze T, Tsuda N. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? Hepatol Res 2006, 35:185-9.
151. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645-52.
152. McHutchison JG, Manns M, Patel K. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061-9.
153. Shiffman ML, Ghany MG, Morgan TR. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007, 132:103-12.
154. Reddy KR, Shiffman ML, Morgan TR. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007, 5:124-9.
155. Shiffman ML, Salvatore J, Hubbard S. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007, 46:371-9.
156. Oze T. Pegylated interferon alpha-2b affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin. J Viral Hepat 2009, 16:578-85.
157. Hiramatsu N. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. J Viral Hepat 2009, 16:586-94.
158. Weiland O, Hollamder A, Mattsson L. Lower-than standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin. J Viral Hepat 2008, 15:641-5.
159. Inoue Y, Hiramatsu N, Oze T. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses. J Viral Hepat in press
160. Omata M, Yoshida H, Toyota J. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 2007, 56:1747-53.
161. Suzuki H, Ohta Y, Takino T. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis. Double blind trial. Asian Med J 1983, 26:423-38.
162. Wildhirt E. Experience in Germany with glycyrrhizinic acid for the treatment of chronic viral hepatitis. Viral Hepatitis and Liver Disease 1994, 658-61. Nishioka KSuzuki HMishiro SOda T. In, eds, Tokyo, Springer-Verlag
163. Arase Y, Ikeda K, Murashima N. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997, 79:1494-500.
164. Ikeda K, Arase Y, Kobayashi M. A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. Dig Dis Sci 2006, 51:603-9.
165. Piperno A, Sampietro M, D'Alba R. Iron stores, response to alpha-interferon therapy and effects of iron depletion in chronic hepatitis C. Liver 1996, 16:248-54.
166. Fong TL, Han SH, Tsai NC. A pilot randomized, controlled trial of the effect of iron depletionon long-term response to alpha-interferon in patients with chronic hepatitis C. J Hepatol 1998, 28:369-74.
167. Herrera JL. Iron depletion is not effective in inducing a virologic response in patients with chronic hepatitis C who failed to respond to interferon therapy. Am J Gastroenterol 1999, 94:3571-5.
168. Fontana RJ, Israel J, LeClair P. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 2000, 31:730-6.
169. Di Bisceglie AM, Bonkovsky HL, Chopra S. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who previously not responded to interferon: a multicenter, prospective randomized, controlled trail. Hepatology 2000, 32:135-8.
170. Yano M, Hayashi H, Yoshioka K. A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan. J Gastroenterol 2004, 39:570-4.
171. Marchesini G, Bianchi G, Merli M. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003, 124:1792-801.
172. McHutchison JG, Everson GT, Gordon SC. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-38.